BR112013006265A2 - espectros antibióticos gerais análogos a arilomicina - Google Patents

espectros antibióticos gerais análogos a arilomicina

Info

Publication number
BR112013006265A2
BR112013006265A2 BR112013006265A BR112013006265A BR112013006265A2 BR 112013006265 A2 BR112013006265 A2 BR 112013006265A2 BR 112013006265 A BR112013006265 A BR 112013006265A BR 112013006265 A BR112013006265 A BR 112013006265A BR 112013006265 A2 BR112013006265 A2 BR 112013006265A2
Authority
BR
Brazil
Prior art keywords
arylomycin
analogs
antibiotic
bioactivity
methods
Prior art date
Application number
BR112013006265A
Other languages
English (en)
Portuguese (pt)
Inventor
Floyd E Romesberg
Peter A Smith
Tucker C Roberts
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of BR112013006265A2 publication Critical patent/BR112013006265A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112013006265A 2010-09-15 2011-08-31 espectros antibióticos gerais análogos a arilomicina BR112013006265A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38298810P 2010-09-15 2010-09-15
PCT/US2011/049967 WO2012036907A2 (en) 2010-09-15 2011-08-31 Broad spectrum antibiotic arylomycin analogs

Publications (1)

Publication Number Publication Date
BR112013006265A2 true BR112013006265A2 (pt) 2016-06-07

Family

ID=45832167

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013006265A BR112013006265A2 (pt) 2010-09-15 2011-08-31 espectros antibióticos gerais análogos a arilomicina

Country Status (10)

Country Link
US (1) US9187524B2 (cg-RX-API-DMAC7.html)
EP (1) EP2616093A4 (cg-RX-API-DMAC7.html)
JP (1) JP2013539751A (cg-RX-API-DMAC7.html)
KR (1) KR20130105659A (cg-RX-API-DMAC7.html)
CN (1) CN103209700A (cg-RX-API-DMAC7.html)
BR (1) BR112013006265A2 (cg-RX-API-DMAC7.html)
CA (1) CA2811295A1 (cg-RX-API-DMAC7.html)
MX (1) MX2013003035A (cg-RX-API-DMAC7.html)
RU (1) RU2013112483A (cg-RX-API-DMAC7.html)
WO (1) WO2012036907A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013003035A (es) 2010-09-15 2013-12-16 Scripps Research Inst Analogos de arilomicina como antibióticos de amplio espectro.
WO2012166665A2 (en) * 2011-05-27 2012-12-06 Rqx Pharmaceuticals, Inc. Broad spectrum antibiotics
US10501493B2 (en) 2011-05-27 2019-12-10 Rqx Pharmaceuticals, Inc. Broad spectrum antibiotics
KR20140140580A (ko) * 2012-03-14 2014-12-09 더 스크립스 리서치 인스티튜트 광범위 항생제 아릴로마이신 유사체
CA2892027A1 (en) * 2012-11-21 2014-05-30 Rqx Pharmaceuticals, Inc. Macrocyclic broad spectrum antibiotics
CN103103261A (zh) * 2013-01-05 2013-05-15 张国新 检测幽门螺杆菌对克拉霉素耐药性试剂盒及制备方法
KR20170027721A (ko) * 2014-05-20 2017-03-10 알큐엑스 파마슈티컬스, 인크. 마크로시클릭 광범위 항생제
CN107106533B (zh) * 2014-10-31 2020-11-06 罗切斯特大学 用于治疗微生物感染的增效组合物
KR20180109858A (ko) 2015-11-20 2018-10-08 알큐엑스 파마슈티컬스, 인크. 마크로시클릭 광범위 항생제
WO2017214534A1 (en) 2016-06-10 2017-12-14 The Scripps Research Institute Synthesis of the arylomycin macrocyclic core
UA126027C2 (uk) * 2017-02-15 2022-08-03 АрКьюЕкс ФАРМАСЬЮТІКЛС, ІНК. Макроциклічні антибіотики широкого спектра
EP3388445A1 (en) * 2017-04-10 2018-10-17 F. Hoffmann-La Roche AG Peptide macrocycles and use thereof in the treatment of bacterial infections
IL288294B (en) 2019-05-28 2022-09-01 Hoffmann La Roche A broad-spectrum macrocyclic antibiotic
CN116023430B (zh) * 2022-12-20 2025-11-25 中国药科大学 2-(2-(2-苯甲酰氨基)乙酰胺)苯甲酸类衍生物及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11514527A (ja) 1995-11-03 1999-12-14 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー バキルス エスピー(Bacillus sp.)用の陽性選択ベクター
US6951840B2 (en) * 2001-08-31 2005-10-04 Eli Lilly And Company Lipoglycopeptide antibiotics
DE102005014245A1 (de) 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Antibakterielle Amid-Makrozyklen V
CN102939095A (zh) * 2010-03-09 2013-02-20 默沙东公司 增强β-内酰胺抗菌药物的活性的桥联脂糖肽类
MX2013003035A (es) 2010-09-15 2013-12-16 Scripps Research Inst Analogos de arilomicina como antibióticos de amplio espectro.
WO2012166665A2 (en) 2011-05-27 2012-12-06 Rqx Pharmaceuticals, Inc. Broad spectrum antibiotics
KR20140140580A (ko) 2012-03-14 2014-12-09 더 스크립스 리서치 인스티튜트 광범위 항생제 아릴로마이신 유사체

Also Published As

Publication number Publication date
MX2013003035A (es) 2013-12-16
RU2013112483A (ru) 2014-10-20
WO2012036907A3 (en) 2012-08-09
US20130281360A1 (en) 2013-10-24
EP2616093A4 (en) 2014-02-26
EP2616093A2 (en) 2013-07-24
WO2012036907A2 (en) 2012-03-22
US9187524B2 (en) 2015-11-17
KR20130105659A (ko) 2013-09-25
CA2811295A1 (en) 2012-03-22
JP2013539751A (ja) 2013-10-28
CN103209700A (zh) 2013-07-17

Similar Documents

Publication Publication Date Title
MX2014011067A (es) Analogos de antibiótico de arilomicina de amplio espectro.
MX2013003035A (es) Analogos de arilomicina como antibióticos de amplio espectro.
BR112016008593A8 (pt) composto, composição farmacêutica, método de regulação de transcrição gênica em uma célula, uso de um composto e método de inibição de reconhecimento mediado por bromodomínio de uma região de acetil lisina de uma proteína
Kubiak et al. Complete genome sequence of Gluconacetobacter xylinus E25 strain—valuable and effective producer of bacterial nanocellulose
BR112016002496A2 (pt) composto de fórmula i, composição farmacêutica, método para inibição de kdm1a, método para tratamento de uma doença mediada por globina, método para atingir um efeito em um paciente, e, método para inibir pelo menos uma função de kdm1a
BR112015026307A2 (pt) heterociclo bicíclicos como inibidores de fgfr
BR112014018027A8 (pt) Composto, composição farmacêutica e usos dos mesmos e métodos para aumentar a inclusão de éxon 7 de ame2 em rnam que é transcrito a partir do gene ame2 e para aumentar a quantidade de proteína smn
BR112012027034A2 (pt) inibidores da arginase e suas aplicações terapêuticas
BR112013005235A2 (pt) "métodos e sistemas para processamento de misturas de açúcar e composições resultantes".
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
BR112021017049A2 (pt) Derivados de tiazol como inibidores de secreção de proteínas
BR112016023559A2 (pt) mutações de deleção
PH12013500152A1 (en) New aminopyrazoloquinazolines
NZ707203A (en) Triazolopyrazine
BR112015014372A2 (pt) inibidores de autotaxina
MY173447A (en) Processing materials
CY1117934T1 (el) Αντιβακτηριακες φαρμακευτικες συνθεσεις
BR112017013258A2 (pt) Derivados de 5-[(piperazin-1-il)-3-oxo-propil]- imidazolidina-2,4-diona como inibidores de adamts para o tratamento de osteoartrite
BR112015006424A2 (pt) grãos fundidos de sub-óxidos de titânio e produtos cerâmicos comportando tais grãos
BRPI0411715B8 (pt) composição farmacêutica compreendendo salinosporamidas
BR112015011697A2 (pt) antibióticos macrocíclicos de amplo espectro
BR112016016853A2 (pt) Compostos contendo nitrogênio, seu uso e seu processo de preparação, composição farmacêutica e seu uso
BR112017006683A2 (pt) método de produção de biopolímeros, método de produção de composto de matriz de biopolímero e composto de matriz de biopolímero
WO2012024405A3 (en) Curcumin compositions and uses thereof
BR102012019673A8 (pt) Reator tubular

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]